Neurologist Dr. Majid Fatuhi frames conditions like Alzheimer's not as a single disease but as the result of a "soup" of biological issues: toxic proteins, inflammation, and damaged blood vessels. Five key contributors are chronic stress, obesity, diabetes, hypertension, and poor sleep, which are largely manageable.

The most important upcoming catalyst in neuroscience is Eli Lilly's TRAILBLAZER-ALZ 3 study, which aims to prevent Alzheimer's in at-risk patients. A positive result is expected to show a much larger effect size than seen in treating existing disease, potentially creating a massive new market and shifting the entire neurodegenerative paradigm.

Alzheimer's is a disease of midlife. Pathological changes in the brain start to occur from around age 30, but the first noticeable cognitive symptoms typically don't manifest until one's late 60s or 70s. This highlights a crucial, multi-decade window for prevention and intervention.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Despite common belief, only about 3-5% of Alzheimer's cases are driven by inherited genetic mutations. The vast majority are linked to lifestyle factors like diet, exercise, and sleep, making it a largely preventable disease if proactive measures are taken early in life.

Current healthcare spending, or "Aging 1.0," focuses on managing age-related decline via retirement homes and late-stage care. The new paradigm, "Aging 2.0," uses biotechnology to prevent the need for this maintenance in the first place, representing a fundamental strategic shift.

The long-term vision for Alt-Pep's diagnostic extends beyond symptomatic patients or those with family histories. The goal is for it to become a routine screening assay, administered annually to the general population to catch the disease at its earliest molecular stages, changing the paradigm from treatment to prevention.

Chronic illnesses like cancer, heart disease, and Alzheimer's typically develop over two decades before symptoms appear. This long "runway" is a massive, underutilized opportunity to identify high-risk individuals and intervene, yet medicine typically focuses on treatment only after a disease is established.